Cereno Scientific is expanding development of CS014 to treat pulmonary hypertension linked to interstitial lung disease.

Research suggests that it is important for clinicians to identify the risk for ILD in patients with SSc so that therapy can be initiated.

Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...

Despite the development of cutting-edge genetic testing techniques and considerable progress in our understanding of the genetic basis of idiopathic pulmonary fibrosis (IPF), missing heritability and ...